An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Evrysdi

Chemical Namerisdiplam
Dosage FormSolution (oral; 60 mg, 0.75 mg/mL)
Drug ClassMiscellaneous
SystemNervous
CompanyGenentech Inc.
Approval Year2020

Indication

  • For the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Evrysdi (risdiplam) Prescribing Information 2020Genentech Inc., South San Francisco, CA
Document TitleYearSource
A two part seamless, open-label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with Type 1 spinal muscular atrophy.2020Hoffmann-La Roche
A two part seamless, multi-center randomized, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of risdiplam (RO7034067) in type 2 and 3 spinal muscular atrophy patients. 2020Hoffmann-La Roche